Matches in DBpedia 2016-04 for { ?s ?p "FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain.[1] It is currently in the preclinical stage of development.[2] The drug was licensed by Flexion from AstraZeneca.[3] FX007 has also attracted interest as a potential treatment of osteoarthritis."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- FX007 abstract "FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain.[1] It is currently in the preclinical stage of development.[2] The drug was licensed by Flexion from AstraZeneca.[3] FX007 has also attracted interest as a potential treatment of osteoarthritis.".
- FX007 comment "FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain.[1] It is currently in the preclinical stage of development.[2] The drug was licensed by Flexion from AstraZeneca.[3] FX007 has also attracted interest as a potential treatment of osteoarthritis.".